Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid

Tetsuo Nakayama, Takashi Ito, Ryoka Ishiyama, Kazuhiko Katayama

Open access · goldAbstract read

In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact, top 80% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

Distinct Innate Immune Responses Following Inoculation With a Replicon mRNA COVID-19 Vaccine.Microbiology and immunology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Tetsuo NakayamaLaboratory of Viral Infection, Ömura Satoshi Memorial Institute, Kitasato University, Tokyo 108-8641, Japan.ORCID 0000-0002-8685-6007

Takashi ItoLaboratory of Viral Infection, Ömura Satoshi Memorial Institute, Kitasato University, Tokyo 108-8641, Japan.

Ryoka IshiyamaGraduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan.

Kazuhiko KatayamaLaboratory of Viral Infection, Ömura Satoshi Memorial Institute, Kitasato University, Tokyo 108-8641, Japan.ORCID 0000-0002-7692-1151

Kitasato University · JPKitasato University Hospital · JP

Funding

Japan Agency for Medical Research and Development 22fk0108650s0401

6 · The paper itself

Abstract

A recombinant SARS-CoV-2 spike protein vaccine (NVX-CoV2373) has been licensed and has a lesser incidence of adverse events. To know the immunological mechanisms of adverse events, the production of cytokines and chemokines was investigated in mice inoculated with NVX-CoV2373. Serum IL-6 was detected on Day 1 of the first and second doses and the IFN-γ, IL-4, IL-10, TNF-α, and IL-6 levels increased on Day 1 of the second dose at the inoculation site. The enhanced production of the inflammatory chemokines (CCL2), homeostatic chemokine (CXCL13), and Th2 chemokine (CCL17) was observed at the inoculation site on Day 1 of the second dose. These findings were compared with data obtained following inoculation with BNT162b2 bivalent vaccine containing omicron BA.4/5. Significantly lower levels of inflammatory chemokines were detected on Day 1 after the first dose of NVX-CoV2373 in sera and inoculation site than those following inoculation with bivalent BNT162b2 (

Indexed as

adverse eventsBNT162b2chemokinecytokineNVX-CoV2373

Identifiers

PMID38006009

DOI10.3390/vaccines11111677

PMCPMC10675389

OpenAlexW4388233865

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.